Psoriasis Archives - Dermatology Advisor

Psoriasis is a chronic disease that affects 2% to 3% of men and women.2 The disease is characterized by plaques and reddish scaly patches. Some women develop pustular psoriasis, which can be life-threatening if severe.3 Although most women with psoriasis notice symptom improvement during pregnancy, 10% to 20% have symptom deterioration.3 The effect of psoriasis on fetal health is unclear.2 Some studies have suggested that psoriasis, which is a TH1-driven disease, contributes to lower birth weight as observed in other TH1-driven diseases.2 The proposed negative effects of psoriasis on fetal health are usually linked to moderate or severe psoriasis. Topical corticosteroids are safe to use during pregnancy, but topical tar products, tazarotene, and retinoids are teratogenic and should be avoided.2,7 Ultraviolent B phototherapy is safe in pregnant women with moderate to severe psoriasis but may compromise folate levels.2 Limited data are available about the safety of biologics during pregnancy, and careful consideration is required before prescribing.2,7

Bimekizumab Compared With Ustekinumab in Plaque Psoriasis Trial

By

October 23, 2019

Bimekizumab met both co-primary end points as well as key secondary end points demonstrating superior to ustekinumab and placebo at Week 16.

Psoriasis

Efficacy of Psoriasis Biologics Lower in Late-Onset Small Plaques and Gigantic Plaques

By

Brandon May

October 21, 2019

In patients with late-onset small plaques, the efficacy of biologic agents, especially TNF inhibitors may be lower than in patients with large plaques.

Psoriasis

Early Serum Ustekinumab Levels Predictive of Psoriasis Treatment Response

By

Emily Pond

October 16, 2019

Adequate drug exposure early in the treatment cycle of psoriasis may be particularly important in determining clinical outcome.

Psoriasis

Scalp Psoriasis Improves With Real-World Use of Cal/BD Aerosol Foam

By

Morgan E. Meissner

October 15, 2019

A newer Cal/BD aerosol foam formulation showed markedly improved signs and severity in patients with scalp psoriasis.

General Dermatology

Patients, Providers Agree on Outcome Measures for Inflammatory Skin Disorders

By

Emily Pond

October 1, 2019

Patients and providers agreed that Skindex instruments are important complements to patient global assessments for determining disease burden and severity in clinical practice.

Psoriasis

NDA for Plaque Psoriasis Treatment Wynzora Submitted for Review

By

Diana Ernst, RPh

September 27, 2019

The treatment was evaluated in a head-to-head phase 3 trial.

Psoriasis

Guselkumab Demonstrates Superiority to Secukinumab for Reducing Psoriasis Area and Severity

By

Brandon May

September 20, 2019

This first ever head-to-head comparison of guselkumab vs secukinumab reported superior long-term efficacy for guselkumab at week 48.

Psoriasis

Examining the Utility, Cost-Effectiveness of Repeat Tuberculosis Testing for Patients With Psoriasis Receiving TNFIs

By

Emily Pond

September 19, 2019

These findings support the belief that serial LTBI testing in low-risk populations may be associated with higher likelihood of false-positive test results, unnecessary costs/treatment, and increased adverse events.

Psoriasis

Patients With Psoriasis Have 2-Fold Higher Risk for Mortality

By

Brandon May

September 17, 2019

The study adds to the current literature by demonstrating the increased and independent risk for mortality-associated psoriasis, using a nationally representative sample of the US population.

Psoriasis

Global Expert Opinion on Psoriasis Severity Established

By

Brandon May

September 11, 2019

This statement rejects the mild, moderate, and severe categories in favor of a dichotomous definition: patients with psoriasis should be classified as either candidates for topical therapy or candidates for systemic therapy.